< BACK TO BLOG
COVID-19 Testing

Orig3n Is Supplying COVID-19 Testing For Massachusetts Nursing Home Residents

COVID-19 testing for nursing home residents

Orig3n has announced a comprehensive solution to enable COVID-19 testing for Massachusetts nursing home residents.

“While our nursing homes, employers, cities and towns are in great need of testing, they face the greatest challenges in coordinating multiple suppliers and service providers to provide testing on the scale that is needed,” said Robin Y. Smith, President and CEO of Orig3n.  “Orig3n offers a single, seamless, end-to-end solution that incorporates specimen collection swabs, healthcare providers to collect specimens, logistics of transporting the specimens back to the laboratory, and testing in our Boston-based high complexity clinical laboratory.  We believe this program will help solve many of the obstacles that are currently preventing the widespread testing that we so desperately need. Orig3n is incredibly excited to offer this solution to our state’s nursing homes in service of their residents, many of whom are at high-risk.  Orig3n’s approach provides a model for the entire nation to make comprehensive testing happen.”

Orig3n is one of the featured laboratories supporting the Long Term Care Facility Surveillance Testing Program and can help nursing homes in Massachusetts become compliant by the July 19 deadline.

Learn more about our offering for nursing homes in Massachusetts here: orig3n.com/covid19/nursinghomes/.

 

 

More information on our COVID-19 tests:

Orig3n is offering the Orig3n 2019 Novel Coronavirus (COVID-19) Test under an Emergency Use Authorization (EUA) from FDA to authorized healthcare providers and institutions nationwide. The test detects the presence of nucleic acid from the virus that causes COVID-19 and is for use with patients suspected of having contracted COVID-19 (subject to current guidance for administration of tests in order to evaluate infection).

Orig3n seeks to be the partner of choice for coordinating and providing COVID-19 testing for defined populations.  The nursing home program is one of many applications for Orig3n’s fully-integrated solution, including:

  • Nursing Homes and Assisted Living Facilities
  • Employer Collection Events. As businesses reopen, Orig3n will partner with employers to coordinate and provide testing for workplaces. This can reduce the risk of workplace hazards associated with COVID19.
  • School Populations. As primary, secondary and higher education institutions reopen in the Fall, Orig3n will partner with these institutions to implement comprehensive testing and risk management programs for their campuses.
  • Governments. As government offices reopen, Orig3n will partner with agencies to provide testing so that our public officials can resume providing critically important services to citizens.
  • City and State Collection Events. Orig3n will partner with cities and states to provide testing for large segments of the population at centralized testing locations.

“As states and municipalities consider ways to get back to ‘normal,’ we see multiple phases to this process,” said Mr. Smith. “Orig3n’s fully-automated, high throughput laboratory and deep experience in sample collection logistics allow us to be the partner of choice for nursing homes, healthcare providers, employers, schools and other institutions nationwide.”

Orig3n’s test is a validated, real-time reverse transcription polymerase chain reaction (RT-PCR) test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in oropharyngeal, nasopharyngeal, anterior nasal, and mid-turbinate nasal swab specimens from individuals suspected of COVID-19.  Test results will be available in 24-36 hours from receipt of specimens in Orig3n’s Boston laboratory.  For more information about the test, please visit http://beta.seaportdx.com/covid19.

The Orig3n 2019 Novel Coronavirus (COVID-19) Test is made available pursuant to the “Immediately in Effect Guidance for Clinical Laboratories and Food and Drug Administration Staff”, which was issued by FDA on February 29, 2020 (as subsequently modified). The EUA will be effective until the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 is terminated.  More information regarding FDA’s authorization can be found FDA’s website at: https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ivd%5C.